$4.55
▼ -1.9% Today
as of Jul 22, 09:05 ET
Last 30 days
Recent Press Releases & News
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?
Overview
52-week range
$3.63
$8.98
17% of range
Avg surprise (last 2)
-45.1%
Avg reaction (last 1)
-3.9%
0% positive
Latest IV / EM
118%
EM ±27.5% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.43 | $-0.24 | -79.2% | — | -3.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.29 | — | — | — | — | financials |
| Thu Aug 7, 2025 | May/2025 | $-0.10 | $-0.09 | -11.1% | — | — | earnings |
| Sun Feb 23, 2025 | Feb 2025 | $-0.42 | — | — | — | — | financials |
| Sun Nov 24, 2024 | Nov 2024 | $-0.25 | — | — | — | — | financials |
| Sun Aug 25, 2024 | Aug 2024 | $-0.53 | — | — | — | — | financials |
| Sun Feb 25, 2024 | Feb 2024 | $0.42 | — | — | — | — | financials |
| Sun Nov 26, 2023 | Nov 2023 | $0.39 | — | — | — | — | financials |
| Sun Aug 27, 2023 | Aug 2023 | $-0.35 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $4M | — | $8M | — | $10M | $11M | $5M | — |
| Operating income | $-5M | — | $-3M | — | $-9M | $-2M | $-12M | — |
| Net income | $-15M | — | $-10M | — | $-15M | $-7M | $-16M | — |
| EPS (diluted) | $-0.43 | — | $-0.29 | — | $-0.42 | $-0.25 | $-0.53 | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21M | $17M | $19M | $8M | $5M | $9M | — | $8M |
| Inventory | $28M | $29M | $34M | $32M | $35M | $39M | $42M | $40M |
| Total current assets | $78M | $82M | $84M | $86M | $84M | $82M | $74M | $81M |
| Total assets | $225M | $232M | $235M | $239M | $238M | $255M | $247M | $254M |
| Long-term debt | — | — | — | — | — | $111M | $106M | $101M |
| Total liabilities | $205M | $198M | $198M | $192M | $190M | $196M | $207M | $200M |
| Total equity | $-28M | $-14M | $-11M | $1M | $2M | $15M | $-4M | $11M |